Page 10 - Lupin

Alkem Lab jumps 4.5% as it launches Favipiravir drug to treat Covid-19

Alkem Laboratories has launched Favipiravir under the brand name 'Alfluenza' in India for the management of mild to moderate cases of Covid-19

Lupin launches Covid-19 drug Favipiravir in India at Rs 49 per tablet

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use of its product

Weekly trading ideas by Religare Broking: Buy Bharti Airtel, Titan Company

TITAN, after the breakout from a consolidation range, is gradually inching higher while holding strongly above the support zone of the long term moving average( 200 EMA) on the daily chart

Lupin gets US FDA approval to market generic diabetes drug in the US

The Mumbai-based company has received a tentative approval from the USFDA for its Empagliflozin tablets

Lupin shuts manufacturing plant after 17 staff test Covid-19 positive

The firm has some 11 manufacturing plants at the Ankleshwar site in Gujarat state, which is spread out over 40 acres and has 984 employees, according to the company website.

Lupin recalls diabetes treatment drug Metformin Hydrochloride in US

Drug major Lupin Ltd on Wednesday said it is voluntarily recalling its diabetes treatment drug Metformin Hydrochloride extended-release tablets in the US market

India's coronavirus drug market set for price war as firms ready launches

Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.

Nifty outlook & stock calls by Anand Rathi: Buy Lupin, Mahanagar Gas

Lupin's stock is making a higher top and higher bottom pattern on the daily chart

US FDA grants orphan drug status to mexiletine hydrochloride: Lupin

The Mumbai-based company's drug NaMuscula (mexiletine hydrochloride) is the first and only licensed product to treat myotonia in adults with non-dystrophic myotonic (NDM) disorders

New launches, cost-control efforts, margin improvement crucial for Lupin

Resolution of compliance issues at Goa, Indore plants are other triggers

Lupin steps up production of key drugs in potential use for Covid-19

Expects US approval for Albuterol soon

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Lupin Q4 net profit up 35% to Rs 390 cr on robust sales, lower tax expenses

In the current times, Lupin has been able to ensure business continuity while safeguarding the health and safety of its employees

Market Ahead, May 28: Top factors that could guide markets today

A total of 24 companies, including TVS Motor, Lupin, and Federal Bank, are scheduled to announce their March quarter results today

Four in a lift, facing the wall: Office etiquette in Covid-19 times

The second of a 3-part series discusses precautions taken by firms to keep employees safe

Bull Spread strategy on Lupin by Nandish Shah of HDFC Securities

Primary trend of the stock is positive where stock price is trading above its 100 and 200-day SMA

Rakesh Jhunjhunwala cuts stake in Titan, Lupin, Escorts in March quarter

Currently, Rakesh Jhunjhunwala and his family's net worth in listed companies stands at Rs 8,517 crore, compared to Rs 8,388 crore as on March 31, 2020.

Top stock picks by CapitalVia Global Research: Buy Sun Pharma, Lupin

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Lupin gets inspection closure report from USFDA for Pithampur plant

Lupin Managing Director Nilesh Gupta, said the company has received the EIR for the plant with Voluntary Action Indicated (VAI) status

Clearance from US drug regulator key for Lupin to sustain stock gains

The recent gains came on Monday after the company received the USFDA approval for its Nagpur facility